Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.
Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.
复制标题
DOI：
10.18632/oncotarget.25053
复制
发表时间：
2018-04-10
期刊：
影响因子：
--
通讯作者：
Akimoto T
中科院分区：
文献类型：
--
作者：
Kageyama SI;Nihei K;Karasawa K;Sawada T;Koizumi F;Yamaguchi S;Kato S;Hojo H;Motegi A;Tsuchihara K;Akimoto T
我们研究了17例接受放疗的I-II期（早期）和IV期（晚期）非小细胞肺癌（NSCLC）患者的肿瘤特异性细胞游离DNA（cfDNA）血浆水平。数字聚合酶链反应（PCR）和靶向测序显示，在早期和晚期NSCLC患者中，总cfDNA水平和肿瘤特异性cfDNA水平均随放疗而增加。我们在IV期NSCLC患者的cfDNA样本中检测到高拷贝数的表皮生长因子受体突变（L 858 R和T790 M），这些患者接受了立体定向体部放疗，以治疗与酪氨酸激酶抑制剂（TKI）治疗失败相关的脑转移。总之，我们的研究表明，放疗增加了血浆中的肿瘤cfDNA水平，并显示出作为诊断早期NSCLC患者或接受分子靶向治疗的患者中耐药肿瘤相关基因突变的指标的潜力。
We investigated the plasma levels of tumor-specific cell-free DNA (cfDNA) in 17 stage I–II (early) and IV (advanced) non-small cell lung cancer (NSCLC) patients who underwent radiotherapy. Digital polymerase chain reaction (PCR) and targeted sequencing showed that total and tumor-specific cfDNA levels increased in response to radiotherapy in both early- and advanced-stage NSCLC patients. We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure. In conclusion, our study demonstrates that radiotherapy increases tumoral cfDNA levels in the plasma and shows potential to serve as an indicator for diagnosing drug-resistant tumor-related gene mutations in early-stage NSCLC patients or those undergoing molecular targeted therapy.